Evidence map›Paper›PMID 42700546›Full record

ArticleClinics (Sao Paulo, Brazil)2026

Preliminary analysis of chromatin accessibility in osteosarcoma tissues.

Fan Ye, Po Hu

Abstract read
In one paragraph

Article in Clinics (Sao Paulo, Brazil), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Fan YeOrthopedics Department, The First Affiliated Hospital of Nanyang Medical College, Henan, China.
Po HuOrthopedics Department, The First Affiliated Hospital of Nanyang Medical College, Henan, China. Electronic address: 286926768@qq.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteosarcoma (OS) is highly invasive, metastatic, and lacks effective therapies, leading to poor prognosis. This study aims to dissect the core epigenetic features of OS from the perspective of chromatin accessibility to elucidate its pathogenesis and identify novel therapeutic targets. ATAC-seq was used to map the global chromatin accessibility profiles of OS tissues versus normal controls. We identified OS-specific aberrantly accessible chromatin regions and delineated enriched transcription factor binding motifs. Key transcription factors were validated by Western blotting and flow cytometry. Notably, in regions with enhanced accessibility, the binding probability of AP-1 family members (including Atf3, Fra1, Fra2, JunB, BATF, AP-1, Jun-AP1, Bach2, and CTCF) was significantly elevated. Further analysis indicates that JunB can inhibit apoptosis of OS cells and enhance their invasive ability, suggesting that it may be related to tumor progression. Overall, JunB, as a candidate molecule with potential research value, is worthy of further verification in subsequent in vivo models and clinical samples to determine its feasibility as an intervention target for OS.

Indexed as

ApoptosisChromatin accessibilityInvasionJunBOsteosarcoma

Identifiers

PMID42700546
PMCPMC13579310

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.